About: Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review
Creator	Kumar, Manish Mukherjee, Santanu Joshi, Chaitanya Kumar, S Mukherjee, S Joshi, P Dalvi, C Dalvi, Sameer Joshi, M Joshi, Madhvi Mazumder, Payal
Source	Elsevier; Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a neoteric virus belonging to the beta coronavirus class has created a global health concern, responsible for an outbreak of severe acute respiratory illness, the COVID-19 pandemic. Infected hosts exhibit diverse clinical features, ranging from asymptomatic to severe symptoms in their genital organs, respiratory, digestive, and circulatory systems. Considering the high transmissibility (R(0): ≤6.0) compared to Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV, the quest for the clinical development of suitable antiviral nanotherapeutics (NTPs) is incessant. We are presenting a systematic review of the literature published between 2003 and 2020 to validate the hypothesis that the pharmacokinetics, collateral acute/chronic side effects of nano drugs and spike proteins arrangement of coronaviruses can revolutionize the therapeutic approach to cure COVID-19. Our aim is also to critically assess the slow release kinetics and specific target site chemical synthesis influenced competence of NTPs and nanotoxicity based antiviral actions, which are commonly exploited in the synthesis of modulated nanomedicines. The pathogenesis of novel virulent pathogens at the cellular and molecular levels are also considered, which is of utmost importance to characterize the emerging nano-drug agents as diagnostics or therapeutics or viral entry inhibitors. Such types of approaches trigger the scientists and policymakers in the development of a conceptual framework of nano-biotechnology by linking nanoscience and virology to present a smart molecular diagnosis/treatment for pandemic viral infections.
has issue date	2020-08-23(xsd:dateTime)
bibo:doi	10.1016/j.envres.2020.110119
bibo:pmid	32846177
has license	no-cc
sha1sum (hex)	a5c97abe51e9a1c67075637afc2e810b6a7b0d1f
schema:url	https://doi.org/10.1016/j.envres.2020.110119
resource representing a document's title	Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review
has PubMed Central identifier	PMC7443328
has PubMed identifier	32846177
schema:publication	Environ Res
resource representing a document's body	covid:a5c97abe51e9a1c67075637afc2e810b6a7b0d1f#body_text
is schema:about of	named entity 'Development' named entity 'transmissibility' named entity 'based' named entity 'late' named entity 'types' named entity 'multiple organ failure' named entity 'hypothesis' named entity 'kinetics' named entity 'Palmieri' named entity 'actions' named entity 'viral transmission' named entity 'severe' named entity 'nanotoxicity' named entity 'Pathway' named entity 'Pathway' named entity 'synthetic' named entity 'protease' named entity 'responsible' named entity 'influenced' named entity 'nanoscience' named entity 'validate' named entity 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'Nalla' named entity 'China' named entity 'infecting' named entity 'NTPs' named entity 'monoclonal antibodies' named entity '2019' named entity 'virology' named entity 'zoonotic' named entity 'emerging' named entity 'family' named entity 'severe' named entity 'agents' named entity 'collateral' named entity 'literature' named entity 'Drug Delivery' named entity 'beta coronavirus' named entity 'drug-resistant' named entity 'infection' named entity 'spike proteins' named entity 'respiratory illness' named entity 'nanomedicines' named entity 'Betacoronavirus' named entity 'genital organs' named entity 'antiviral' named entity 'interferons' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'neoteric' named entity 'pathogenesis' named entity 'Middle East respiratory syndrome coronavirus' named entity 'viral infections' named entity 'viral entry' named entity 'SARS-CoV-2' named entity 'China' named entity 'COVID-19 pandemic' named entity 'SARS-CoV' named entity 'nanotoxicity' named entity 'viral Pandemic' named entity 'Metabolic Pathway' named entity 'Antiviral' named entity 'Metabolic Pathway' named entity 'Antiviral' named entity 'drug delivery' named entity 'virus' named entity 'nanomaterials' named entity 'virus' named entity 'HIV-1' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'Immunization'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software